Competing designs for phase I clinical trials: A review

Statistics in Medicine

Volumn 21, Issue 18, 2002, Pages 2757-2770

  Rosenberger, William F ^a,b   Haines, Linda M ^c  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Continual reassessment method; Decision theory; Escalation with overdose control; Maximum tolerated dose; Quantile estimation; Random walks rules

Indexed keywords

DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE; DRUG RESEARCH; DRUG TOLERANCE; EXPERIMENTAL DESIGN; HUMAN; INTERMETHOD COMPARISON; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SIMULATION; STATISTICAL ANALYSIS;

CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; RESEARCH DESIGN; STATISTICS;

EID: 0037201011     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1229     Document Type: Article

References (55)

1. Dose response studies. I. Some design considerations
2. Anticancer drugs
3. Perceptions of cancer patients and their physicians involved in phase I trials
4. Ethics and practice: Alternative designs for phase III randomized clinical trials
5. Recursive nonparametric testing for dose-response relationships subject to downturns at high doses
6. Adaptive statistical procedures for the analysis of nonmonotone dose-response relationships
7. Design of phase I and II clinical trials in cancer: Astatistician's view
8. Accelerated fitration designs for phase I clinical trials in oncology
9. A comparison of two phase I trial designs
10. Design and analysis of phase I clinical trials
11. Continual reassessment method: A practical design for phase I clinical trials in cancer
12. Random walks for quantile estimation
13. A random walk rule for phase I clinical trials
14. Bayesian decision procedures for dose determining experiments
15. Bayesian decision procedures with application to dose-finding studies
16. Cancer phase I clinical trials: Efficient dose escalation with overdose control
17. Small-sample confidence sets for the MTD in a phase I clinical trial
18. Operating characteristics of the standard phase I clinical trial design
19. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
20. Bayesian methods for phase I clinical trials
21. Continual reassessment method: A likelihood approach
22. Methods for dose finding studies of cancer clinical trials: A review and results of a Monte Carlo study
23. The continual reassessment method in cancer phase I clinical trials: A simulation study
24. Some practical improvements in the continual reassessment method for phase I studies
25. New directions in adaptive designs
26. QUEST: A Bayesian adaptive psychometric method
27. Practical modifications of the continual reassessment method for phase I clinical trials
28. A curve-free method for phase I clinical trials
29. A stopping rule for the continual reassessment method
30. Another look at two phase I clinical trial designs
31. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses
32. Improved designs for dose escalation studies using pharmacokinetic measurements
33. Consistency of the continual reassessment method under model misspecification
34. Sequential search of an optimal dosage I
35. Optimal Bayesian-feasible dose escalation for cancer phase I clinical trials
36. Flexible algorithms for creating and analyzing adaptive sampling procedures
37. Bayesian decision procedures based on logistic regression models for dose-finding studies
38. Bayesian design for dose-response curves with penalized risk
39. Dose finding using the biased coin up-and-down design and isotonic regression
40. Properties of frequency distributions induced by general 'up-and-down' methods for estimating quantiles
41. Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs
42. Up-and-down designs II: Exact treatment moments
43. Toxicity in sequential dose-response experiments
44. Design of experiment for bioassay
45. A clinical experiment in bone marrow transplantation: Estimating a percentage point of a quantal response curve
46. Selection of dose levels for estimating a percentage point of a logistic quantal response curve
47. Practical implementation of a modified continual reassessment method for dose-finding trials
48. Bayesian approaches to randomized clinical trials
49. Two-sample continual reassessment method
50. A quantitative study of the continual reassessment method in the presence of heterogeneity
51. Simple designs for phase I clinical trials of long-term toxicities